問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

國立臺灣大學醫學院

Division of General Internal Medicine

更新時間：2023-09-19

陳培哲CHEN, PEI-JER
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳培哲

List

104Cases

2018-03-31 - 2026-04-20

IIT

Phase I/II

Active
A Phase I/II Open Label Study to Evaluate Safety and the Prophylactic Effect on Recurrence of Anti-PD1 Monotherapy, P1101 Monotherapy, and Sequential Administration of P1101 and Anti-PD1 After Curative Surgery of HBV-related HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    P1101

Participate Sites
1Sites

Recruiting1Sites

2017-12-01 - 2020-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-04-01 - 2020-12-31

Phase III

Completed
An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Interferon Treatment-Naive Subjects with Chronic HCV Genotype 2 Infection

  • Condition/Disease

    Chronic Hepatitis C Infection

  • Test Drug

    P1101

Participate Sites
20Sites

Terminated20Sites

2021-01-04 - 2025-12-31

IIT

Others

Active
An open-label, multicenter, randomized, active control study, comparing P1101 monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B under long-term nucleos(t)ide analogue therapy

  • Condition/Disease

    chronic hepatitis B virus infection

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-02-24 - 2025-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-07-01 - 2024-12-31

Phase I

Active
A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection

  • Condition/Disease

    Chronic Hepatitis B Infection/Chronic Hepatitis D Infection

  • Test Drug

    P1101 (Ropeginterferon alfa-2b)

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-07-01 - 2027-02-26

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2024-07-15 - 2026-08-31

Phase I

Active
A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Advanced or Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2021-08-01 - 2027-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2008-06-01 - 2010-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB